16-2102849-A-G
Position:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1
The NM_001009944.3(PKD1):c.8913T>C(p.Ala2971Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00547 in 1,594,920 control chromosomes in the GnomAD database, including 450 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.032 ( 241 hom., cov: 32)
Exomes 𝑓: 0.0029 ( 209 hom. )
Consequence
PKD1
NM_001009944.3 synonymous
NM_001009944.3 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.96
Genes affected
PKD1 (HGNC:9008): (polycystin 1, transient receptor potential channel interacting) This gene encodes a member of the polycystin protein family. The encoded glycoprotein contains a large N-terminal extracellular region, multiple transmembrane domains and a cytoplasmic C-tail. It is an integral membrane protein that functions as a regulator of calcium permeable cation channels and intracellular calcium homoeostasis. It is also involved in cell-cell/matrix interactions and may modulate G-protein-coupled signal-transduction pathways. It plays a role in renal tubular development, and mutations in this gene cause autosomal dominant polycystic kidney disease type 1 (ADPKD1). ADPKD1 is characterized by the growth of fluid-filled cysts that replace normal renal tissue and result in end-stage renal failure. Splice variants encoding different isoforms have been noted for this gene. Also, six pseudogenes, closely linked in a known duplicated region on chromosome 16p, have been described. [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.93).
BP6
Variant 16-2102849-A-G is Benign according to our data. Variant chr16-2102849-A-G is described in ClinVar as [Likely_benign]. Clinvar id is 257031.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-2102849-A-G is described in Lovd as [Benign]. Variant chr16-2102849-A-G is described in Lovd as [Likely_benign].
BP7
Synonymous conserved (PhyloP=-1.96 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.108 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PKD1 | NM_001009944.3 | c.8913T>C | p.Ala2971Ala | synonymous_variant | 24/46 | ENST00000262304.9 | NP_001009944.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PKD1 | ENST00000262304.9 | c.8913T>C | p.Ala2971Ala | synonymous_variant | 24/46 | 1 | NM_001009944.3 | ENSP00000262304.4 |
Frequencies
GnomAD3 genomes AF: 0.0319 AC: 4444AN: 139172Hom.: 242 Cov.: 32
GnomAD3 genomes
AF:
AC:
4444
AN:
139172
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00775 AC: 1928AN: 248664Hom.: 98 AF XY: 0.00559 AC XY: 755AN XY: 135054
GnomAD3 exomes
AF:
AC:
1928
AN:
248664
Hom.:
AF XY:
AC XY:
755
AN XY:
135054
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00293 AC: 4262AN: 1455626Hom.: 209 Cov.: 34 AF XY: 0.00248 AC XY: 1798AN XY: 724176
GnomAD4 exome
AF:
AC:
4262
AN:
1455626
Hom.:
Cov.:
34
AF XY:
AC XY:
1798
AN XY:
724176
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0320 AC: 4458AN: 139294Hom.: 241 Cov.: 32 AF XY: 0.0308 AC XY: 2089AN XY: 67908
GnomAD4 genome
AF:
AC:
4458
AN:
139294
Hom.:
Cov.:
32
AF XY:
AC XY:
2089
AN XY:
67908
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Oct 09, 2017 | - - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | May 11, 2021 | This variant is associated with the following publications: (PMID: 9285784, 17574468, 22008521, 22383692) - |
Polycystic kidney disease, adult type Benign:1
Benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jun 02, 2020 | - - |
Polycystic kidney disease Benign:1
Benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The PKD1 p.Ala2971Ala variant was identified in 5 of 698 proband chromosomes (frequency: 0.007) from individuals or families with ADPKD, and was not identified in 442 control chromosomes from healthy individuals (Bataille_2011, Garcia-Gonzalez_2007, Rossetti_2012). The variant was also identified in dbSNP (ID: rs9926309) “With NA allele”, in 1000 Genomes Project in 190 of 5013 chromosomes (frequency: 0.0379), and in the NHLBI GO Exome Sequencing Project (ESP) in 5 of 8580 European American and in 394 of 4390 African American alleles. In addition, the variant is identified in the Exome Aggregation Consortium database (March 14, 2016) in 1155 of 119736 chromosomes (freq. 0.01) in the following populations: African in 1053 (57 homozygous) of 10158 chromosomes (freq. 0.1037), other in 5 of 886 chromosomes (freq. 0.006), Latino in 65 of 11538 chromosomes (freq. 0.006), European (Non-Finnish) in 29 of 65418 chromosomes (freq. 0.0004), South Asian in 2 of 16504 chromosomes (freq. 0.0001), East Asian in 1 of 6610 chromosomes (freq. 0.0001) but was not seen in a Finish population, increasing the likelihood this could be a low frequency benign variant. The variant is also listed in GeneInsight COGR (classified as benign), and in ADPKD Mutation Database (6x as likely neutral). The p.Ala2971Ala variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information, this variant meets our laboratory criteria to be classified as benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at